RT Journal Article
SR Electronic
T1 Genome-wide association analysis identifies ancestry-specific genetic variation associated with medication response in the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.24.22269036
DO 10.1101/2022.01.24.22269036
A1 Li, Josephine H.
A1 Brenner, Laura N.
A1 Kaur, Varinderpal
A1 Figueroa, Katherine
A1 Udler, Miriam S.
A1 Leong, Aaron
A1 Investigators, MAGIC
A1 Mercader, Josep M.
A1 Florez, Jose C.
YR 2022
UL http://medrxiv.org/content/early/2022/01/24/2022.01.24.22269036.abstract
AB Background Characterization of genetic variation that influences response to glucose-lowering medications is instrumental to precision medicine for treatment of type 2 diabetes (T2D). SUGAR-MGH examined the acute response to two anti-diabetes medications in order to understand the functional relevance of known T2D- and glycaemic trait-associated genetic loci.Methods 1,000 participants at risk for T2D from diverse ancestries underwent sequential glipizide and metformin challenges. A genome-wide association study was performed using the Illumina Multi-Ethnic Genotyping Array. Imputation was performed with the TOPMed reference panel. Multiple linear regression using an additive model tested for association between variants and primary endpoints of drug response. We evaluated the influence of 804 unique T2D and glycaemic trait-associated variants on SUGAR-MGH outcomes and performed colocalization analyses to identify shared genetic signals.Findings Five genome-wide significant variants were associated with metformin or glipizide response. The strongest association was between an African ancestry-specific variant (minor allele frequency=0·026) at rs149403252 and lower fasting glucose following metformin, adjusted for baseline glucose (p=1·9×10−9), with a 0·94 mmol/L larger decrease in fasting glucose after metformin. We identified associations between T2D-associated variants and glycaemic response, including the T2D-protective C allele of rs703972 near ZMIZ1 and increased levels of active GLP-1 (p=1·6×10−5), supporting the role of alterations in incretin levels in T2D pathophysiology.Interpretation We present a well phenotyped, densely genotyped, multi-ancestry resource to study gene-drug interactions, uncover novel variation associated with response to common anti-diabetes medications, and provide insight into mechanisms of action of T2D-related variation.Funding US National Institutes of Health.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01762046Funding StatementThis work was conducted with support from National Institutes of Health/NIDDK awards R01 DK088214, R03 DK077675, and P30 DK036836; from the Joslin Clinical Research Center from its philanthropic donors; and the Harvard Catalyst: The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Awards M01-RR-01066, 1 UL1 RR025758-04 and 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic health care centres). JHL received individual support from NIH T32DK007028. LNB is supported by NIH K23DK125839. MSU is supported by NIDDK K23DK114551. AL is supported by grant 2020096 from the Doris Duke Charitable Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Mass General Brigham Human Research Committee IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe complete summary statistics from this study will be deposited and made available at the Common Metabolic Diseases Knowledge Portal (https://hugeamp.org) and the GWAS Catalog following final publication in a peer-reviewed journal. Additional data requests should be sent by email to the corresponding author.